Hemovent GmbH, an Aachen, Germany-based artificial lung platform developer, received an undisclosed funding as an extention of its Series A financing round.
Backers included all existing investors as well as new investor 1st Capital Partner.
Led by Christof Lenz, co-founder and CEO, Hemovent is an emerging medical device company that has developed small and self-contained fully portable artificial lungs for ExtraCorporeal Membrane Oxygenation (ECMO) /ExtraCorporeal Life Support (ECLS) applications designed to support or replace heart and lung function in the event of cardiac and/or respiratory failure.
The funding follows the announcement last month that the company has completed the first series of in vivo trials for the initial application of its novel and portable Artificial Lung technology platform, designed for a range of indications from ExtraCorporeal CO2 Removal (ECCO2R) to ExtraCorporeal Life Support (ECLS).
These applications, ECCO2R and ECLS, are also referred to as ExtraCorporeal Membrane Oxygenation (ECMO): establishment of an artificial external blood circuit with a portable pump and gas exchanger system to support lung function only or even establish a full cardiopulmonary bypass.
ECMO as a temporary “artificial lung” either provides respiratory support to patients whose lungs are so damaged they cannot perform their function, or as a temporary “life support system” and takes over the heart function in case of acute heart failure.
The Hemovent ECMO/ ECLS System is not approved for human use.